Full text in:
In this study, we investigated the use of erythropoietin as an early marker of chronic kidney disease (CKD). Methods: 72 patients with CKD (42 % male) aged 51,7 ± 13,4 years and 10 healthy subjects (50 % male) aged 49,6 ± 11,2 years were included in our study. All patients have full clinical diagnostics of CKD and blood level of erythropoietin. Results: It was shown that blood level of erythropoietin in patients with 1, 2 and 3rd stages of CKD was significantly (p < 0.05) higher than in healthy subjects. The patients with 4 stage of CKD have erythropoietin level comparable to healthy subjects. Conclusion: Increased erythropoietin levels in blood associated with the progression of CKD, which can be used in the early diagnosis of CKD.
Borodulin VB, Bychkov EN, Protopopov AA, Rebrov AP, Shevchenko OV, Nesterenko OV, Kiselev AR, Bobyleva EV. Erythropoietin is a marker of chronic kidney disease at the pre-clinical stage. Fundamental Research 2013; (11-1): 22-26.